Marin Jukić, PhD
Dr. Marin Jukić earned his MSc degree in pharmacy at the Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Serbia and his PhD at the Department of Physiology and Cell Biology, Faculty of Medicine, Ben Gurion University, Israel. Marin Jukić was employed at the Faculty of Medicine, Ben Gurion University as a teaching assistant for histology from October 2011. to October 2014. Marin Jukić was employed as a postdoctoral scientist at the Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. Marin Jukić was also employed as a teaching assistant and lecturer at the Medical School of Karolinska Institute teaching pharmacology from March 2015. to March 2017.
Dr. Marin Jukić research is focused on brain development, monaminergic neurotransmission, as well as on genetics, epidemiology, and clinical properties of bipolar disorder and major depression. Dr. Marin Jukić was invited as a speaker to four international conferences (at least 2,000 registered participants at each). Dr. Marin Jukić serves at the European college for Neuropsychopharmacology as the head of junior member advisory panel, member of workshop committee, and member of scientific committee. Dr. Marin Jukić is a visiting scientist at the Pharmacogenomics Section, Karolinska Institute and at the Department for Clinical Psychiatry, Medical University of Vienna. Dr. Marin Jukić serves as a member of editorial board and associated editor of Drug Metabolism Reviews (IF:4.058). Throughout the career, Dr. Marin Jukić was awarded with several highly competitive awards including three poster awards at ECNP annual meetings (2013, 2014, and 2016) and IBRO InEurope short-stay grant (top 20 young neuroscientists in Europe are awarded every year).
Jukić MM, Opel N, Strom J, Carrillo-Roa T, Miksys S, Novalen M, Renblom A, Sim SC, Peñas-Lledó EM, Courtet P, LLerena A, Baune BT, de Quervain DJ, Papassotiropoulos A, Tyndale RF, Binder EB, Dannlowski U, Ingelman-Sundberg M.Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal serotonin homeostasis impairment. Molecular Psychiatry 2017 (M21a, IF:13,314)
- Jukić MM, Carrillo-Roa T, Bar M, Becker G, Jovanovic VM, Zega K, Binder EB, Brodski C. Abnormal development of monoaminergic neurons is implicated in mood fluctuations and bipolar disorder. Neuropsychopharmacology 2015 (M21a, IF: 7,833)
- Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry 2019 (IF: 18,329)
- Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. American Journal of Psychiatry 2018 (IF: 13,655)